Cromos Pharma, where the patients are

R&D Trends

University of Edinburgh, Selcia to develop sleeping sickness treatment

Wednesday, February 12, 2014 01:18 PM

Scientists from the University of Edinburgh, working with international life sciences CRO Selcia, are launching a $4.1 million project to design novel treatments for sleeping sickness, which is spread by the bite of the tsetse fly and is prevalent in west and central Africa. It can damage the nervous system and cause coma, organ failure and death.

More... »

CRF Health eCOA webinar series

Innate Pharma acquires ANTI-NKG2A from Novo Nordisk

Monday, February 10, 2014 10:19 AM

Innate Pharma has acquired full development and commercialization rights to the anti-NKG2A antibody, a first-in-class immune checkpoint inhibitor ready for phase II development in oncology from global healthcare company Novo Nordisk.

More... »

Report: Absence of 2014 blockbuster drug launches puts R&D productivity at risk

Monday, February 10, 2014 09:54 AM

The past two years have brought a surge of R&D productivity, driving investor confidence and increasing market performance, but 2014 looks to tell a different tale according to a new report from EP Vantage, a source of life science market intelligence and analysis.

More... »

Seven California institutions awarded $40M to create Center of Excellence in Stem Cell Genomics

Thursday, February 6, 2014 11:43 AM

A team bringing together experts and investigators from seven different major California institutions has been awarded $40 million to create a new Center of Excellence in Stem Cell Genomics, by California's stem cell agency, the California Institute for Regenerative Medicine.

More... »

Merck forms collaborations with Amgen, Incyte, Pfizer

Thursday, February 6, 2014 11:41 AM

Merck has signed three separate clinical collaboration agreements, through subsidiaries, with Amgen, Incyte and Pfizer to evaluate novel combination regimens with MK-3475, Merck’s investigational anti-PD-1 immunotherapy. Financial terms have not been disclosed.

More... »

NIH, industry and nonprofits join forces to speed validation of disease targets

Wednesday, February 5, 2014 01:02 PM

The National Institutes of Health, 10 biopharmaceutical companies and several nonprofit organizations have launched an unprecedented partnership to transform the current model for identifying and validating the most promising biological targets of disease for new diagnostics and drug development.

More... »

Ablynx, Merck collaborate

Monday, February 3, 2014 09:08 AM

Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies,has entered into a second research collaboration and licensing agreement with a subsidiary of Merck.

More... »

Edison Pharmaceuticals, Dainippon Sumitomo Pharma collaborate

Friday, January 31, 2014 12:52 PM

Edison Pharmaceuticals, a specialty pharmaceutical company dedicated to developing treatments for children and adults with orphan mitochondrial diseases, has entered into a strategic alliance valued at up to $4.295 billion with Dainippon Sumitomo Pharma (DSP) for the development of drugs targeting cellular energy metabolism.

More... »

Curie-Cancer, Servier renew partnership in cancer research

Wednesday, January 29, 2014 01:17 PM

Curie-Cancer, the body that leads the Institut Curie's industry partner research activity, and Servier, an independent French pharmaceutical research company, have renewed their partnership with the aim of identifying therapeutic targets for treating triple negative breast cancers. The partnership will continue for three more years.

More... »

NIBIO, Aeras, CREATE to advance Japanese TB vaccine technology

Wednesday, January 29, 2014 01:13 PM

Japan's National Institute of Biomedical Innovation (NIBIO), Aeras and Create Vaccine (CREATE) have signed a collaboration for the preclinical and clinical development of new mucosal tuberculosis (TB) vaccines based on NIBIO's human parainfluenza type-2 (rhPIV2) vector technology.

More... »

CenterWatch Drugs in Clinical Trials



Browse by:


April 14

Proposal calls for back-to-back trials to measure efficacy and effectiveness prior to FDA approval

Study: Minority populations under-represented in cancer trials, but have higher rates of incidence

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly


Make way for mobile health in clinical trials
Despite patient retention, data quality benefits, regulatory hurdles persist

Global clinical trial laboratories decentralize
Regional labs reducing complexity, delivering cost and time savings

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly


Strategic alliances hit bumps in the road
Mixed relationship performance driving new approaches

Tapping community hospitals for clinical trial volunteers
New study finds high potential but infrastructure, resources are lacking

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.


Featured Jobs